Shareholders of Mabtech
Shareholders of Mabtech IK Investment Partners has acquired Mabtech IK Investment Partners
We have been mandated by the owners of a Swedish biotech company in connection with the evaluation of a potential sale of the Company. The company is focused on developing and manufacturing high-quality monoclonal antibodies, kits, and instruments for analyses of immune responses and the immune system in e.g. infectious diseases, cancer, allergy, transplantations, vaccines. The products are mainly sold for research, but are also sold to diagnostic companies. The company is experiencing rapid growth and strong profitability. During the 12 months to June 2019 the company recorded sales of ca €12m (36% growth) and EBITDA margin in excess of 45%.
We ran a focused but highly competitive process focusing on potential PE buyers with experience / knowledge in the Life Science sector and select industrial buyers. Interest from PE buyers was clearly stronger. We focused on early pre-marketing meetings with potential buyers to describe the company and opportunity. We got 5 potential buyers to complete their commmercial due diligence even before indicative offers, which made us comfortable about the level of commitment to the deal. We ran the key negotiation about valuation around the time of indicative offers and got most of the serious bidders to increase their offers. We decided to move forward with only two potential buyers in a DD phase in order to be able to run a focused on quick process. We managed to sign the deal with a local Swedish PE house in less than 3 weeks after indicative offers. No conditions to closing - closing will take place on Dec 12.
IK Investment Partners
Evli Corporate Finance AB
Evli has been providing corporate finance services since 1997. Today Evli has around 20 professionals at our Helsinki and Stockholm office, supported by a network of more than 20 senior advisors with previous top management experience from a range of industries. We advise our clients on mergers and acquisitions, disposals, leveraged buy-outs, joint ventures and various capital market transactions including public and private fund raisings. We are generalists in terms of industries that we work with, but have a dedicated healthcare team and have significant experience from transactions in the following sectors: mining, raw materials, consumer goods & retail, TMT, building / building products, and real estate. Our clients are typically companies, private and public, and their owners as well as institutional investors and private equity companies active or interested in the Nordic countries. Since 2007 we have advised on more than 150 transactions with a combined value of over € 10 billion.